Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

OCTOBER 29, 2013

Pharmatest Services Ltd attends CIBD conference in Miami with scientific presentations

Pharmatest Services Ltd attends 13th international conference on cancer-induced bone disease (CIBD) held in Miami, FL, USA on November 6 – 9, 2013. In the conference Pharmatest presents scientific presentations that demonstrate efficacy of customer compounds for treating CIBD.

About half of patients that die from cancer have bone involvement. CIBD develops commonly in many cancers such as breast, prostate and lung cancer and multiple myeloma, and it can also be induced by treatments of primary cancer such as with glucocorticoids, estrogen or androgen deprivation, or chemotherapy-induced ovarian failure.

Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) that offers preclinical efficacy services for the pharmaceutical industry in the fields of skeletal diseases and oncology, including high quality research models that are clinically predictive for CIBD. The International Conference on CIBD is the leading scientific event concentrating on CIBD research organized annually by the International Bone and Mineral Society (IBMS).

Pharmatest attends the CIBD conference with two scientific presentations that demonstrate efficacy of customer compounds for treating CIBD. The studies described in the presentations were performed in collaboration with Bayer Pharma AG related to breast cancer and Virobay Inc related to multiple myeloma.

Both Bayer (see Bayer news) and Virobay Inc give credit for Pharmatest. Dr. Leslie Holsinger, Vice President of Biology, Virobay Inc. says: "Virobay has worked with Pharmatest on both in vitro and in vivo model analysis of drug candidates and we are very pleased with the excellent quality of their work and the high level of scientific expertise they provide to our studies.”

Jussi Halleen, CEO of Pharmatest says: “We are happy to present the exiting new data in the CIBD conference. The models used in the studies have convincingly demonstrated their clinically predictive power earlier, and the obtained results are very good news for our customers whose compounds were tested in the studies.”